Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas

Tumor Biology

Volumn 19, Issue 6, 1998, Pages 470-476

  Elsasser Beile U ^a,b   Kolble N ^a   Grussenmeyer, T ^a   Schultze Seemann, W ^a   Wetterauer, U ^a   Gallati, H ^a   Schulte Monting J ^a   Von Kleist, S ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Experimental Research Group   (Germany)

Author keywords

Cancer patients; Th1 Th2 cytokine response

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER IMMUNOLOGY; CANCER PATIENT; CANCER SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LEUKOCYTE CULTURE; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; T LYMPHOCYTE SUBPOPULATION; UROGENITAL TRACT CANCER;

EID: 0031763213     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030039     Document Type: Article

References (31)

1. Abbas AK, Murphy KM, Sher A: Functional diversity of helper T lymphocytes. Nature 1996;383:787-793.
2. Abehsira-Amar O, Gibert M, Joliy M, Theze J, Jankovic DL: IL-4 plays a dominant role in the differential development of Th0 into Th1 and Th2 cells. J Immunol 1992;148:3820-3829.
3. Röcken M, Saurat J-H, Hauser C: A common precursor for CD4+ T cells producing IL-2 or IL-4. J Immunol 1992;148:1031-1036.
4. Elson LH, Nutman TB, Metcalfe DD, Prussin C: Flow cytometric analysis for cytokine production identifies T helper 1, T helper 2, and T helper 0 cells within the human CD4+CD27- lymphocyte subpopulation. J Immunol 1995;154:4294-4301.
5. Swain SL, Weinberg AD, English M, Huston G: IL-4 directs the development of Th2-like helper effectors. J Immunol 1990;145:3796-3806.
6. Schmitz J, Assenmacher M, Radbruch A: Regulation of T helper cell cytokine expression: Functional dichotomy of antigen-presenting cells. Eur J Immunol 1993,23:191-199.
7. Doherty TM, Coffman RL: Leishmania antigens presented by GMCSF-derived macrophages protect susceptible mice against challenge with Leishmania major. J Immunol 1993;150:5476-5483.
8. H2 cell antigen receptors in experimental leishmaniasis. Science 1993;259:1457-1460.
9. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM: Reciprocal expression of interferon γ or interleukin 4 during the resolution of progression of murine leishmaniasis. J Exp Med 1989;169:59-72.
10. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK: Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993;177:1505-1509.
11. Modlin RL, Mehra V, Wong L, Fujimiya Yoshiaki, Chang W-C, Horwitz DA, Bloom BR, Rea TH, Pattengale PK: Suppressor T lymphocytes from lepromatous skin lesions. J Immunol 1986;137:2831-2834.
12. Powrie F, Menon S, Coffman RL: Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur J Immunol 1993;23:2223-2229.
13. H2 switch is a critical step in the etiology of HIV infection. Immunol today 1993;14:107-111.
14. Barcellini W, Rizzardi GP, Borghi MO, Fain C, Lazzarin A, Meroni PL: TH1 and TH2 cytokine production by peripheral blood mononuclear celis from HIV-infected patients. AIDS 1994;8:757-762.
15. Peltz G: A role for CD4+ T cell subsets producing a selective pattern of lymphokines in the pathogenesis of human chronic inflammatory and allergic diseases. Immunol Rev 1991;123:23-35.
16. Elsässer-Beile U, von Kleist S, Fischer R, Martin M, Wetterauer U, Gallati H, Schulte Mönting J: Impaired cytokine production in whole blood cell cultures of patients with urological carcinomas. J Cancer Res Clin Oncol 1993;119:430-433.
17. Elsässer-Beile U, von Kleist S, Martin M, Gallati H, Schulte Mönting J: Impaired cytokine production in whole blood cell cultures of patients with gynecological carcinomas in different clinical stages. Br J Cancer 1993;68:32-36.
18. Elsässer-Beile U, von Kleist S, Gallati H: Evaluation of a test system for measuring cytokine production in human whole blood cell cultures. J Immunol Meth 1991;139:191-195.
19. Rey A, Klein B, Zaguri D, Thierry C, Serrou B: Diminished interleukin-2 activity production in cancer patients bearing solid tumors and its relationship with natural killer cells. Immunol Lett 1983;6:175-178.
20. Wanebo HJ, Pace R, Hargett S, Katz D, Sando J: Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients. Cancer 1986;57:656-662.
21. Yron I, Schickler M, Fisch B, Pinkas H, Ovadia J, Witz IP: The immune system during the pre-cancer and the early cancer period. IL-2 production by PEL from post-menopausal women with and without endometrial carcinoma. Int J Cancer 1986;38:331-338.
22. Bubenik J, Kieler J, Tromholt V, Hermann G, Jandlová T: Defect in lectin-induced interleukin 2 production by peripheral blood lymphocytes of patients with invasive urinary bladder carcinoma. Immunol Lett 1988;18:115-118.
23. Elsässer-Beile U, von Kleist S, Stähle W, Schurhammer-Fuhrmann C, Schulte Mönting J, Gallati H: Cytokine levels in whole blood cell cultures as parameters of the cellular immunological activity in patients with malignant melanoma and basal cell carcinoma. Cancer 1993;71:231-236.
24. Pellegrini P, Berghella AM, Del Beato T, Cicia S, Adorno D, Casciani CU: Deregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 1996;42:1-8.
25. Berghella AM, Pellegrini P, Del Beato T, Marini M, Tomei E, Adorno D, Casciani CU: The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back. Cancer Immunol Immunother 1998;45:241-249.
26. Rice SQJ, Crane IJ, Scully C, Prime SS: Production of a suppressor of lymphocyte proliferation by two human oral carcinoma cell lines. Scand J Immunol 1992;36:443-452.
27. Yoshino I, Yano T, Miyamoto M, Yamada K, Kajii Y, Onodera K, Ishida T, Sugimachi K, Kimura G, Nomoto K: Characterization of lung squamous cell carcinoma-derived T-cell suppressive factor. Cancer 1993;72:2347-2357.
28. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB: Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 1995;5:67-68.
29. Fortis C, Foppoli M, Gianotti L, Galli L, Citterio G, Consogno G, Gentilini O, Braga M: Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett 1996;104:1-5.
30. Lissoni P, Rovelli F, Tisi E, Brivio F, Ardizzoia A, Barni S, Tancini G, Saudelli M, Cesana E, Vigano MG: Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors. J Biol Regul Homeost Agents 1995;9:146-149.
31. Wojciechowska-Lacka A, Matecka-Nowak M, Adamiak E, Lacki JK, Cerkaska-Gluszak B: Serum levels of interleukin-10 and interleukin-6 in patients with lung cancer. Neoplasma 1996;43:155-158.